BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 26, 2025
Home » Authors » Stacy Lawrence

Stacy Lawrence

Articles

ARTICLES

Study defines diabetes patients in five groups, with Rx, Dx implications

March 12, 2018
By Stacy Lawrence
Researchers have defined five categories of diabetes patients, rather than the longstanding basic division into type 1 and type 2. That is an advance that could better enable health care providers to both combat the most aggressive forms of the disease as well as to help equip them to guide early treatment and prevention efforts in the lowest risk populations.
Read More

Study finds that a single PSA test doesn't help prevent prostate cancer deaths

March 9, 2018
By Stacy Lawrence

5 groups for diabetes patients defined, yielding implications for diagnosis and treatment

March 8, 2018
By Stacy Lawrence

Siemens Healthineers IPO valuation of $38B makes it a top 10 public med-tech company

March 7, 2018
By Stacy Lawrence
An IPO for the health care business of Munich, Germany-based Siemens AG has been a long-time coming. Almost three years ago in May 2014, the German conglomerate laid out a five year plan to get it through 2020. That's when it first said it would separately manage its health care business, which was subsequently, but perhaps not eloquently, renamed Siemens Healthineers AG in May 2016.
Read More

Predicting cognitive problems in the elderly with retinal imaging of blood vessels

March 6, 2018
By Stacy Lawrence

Senseonics heads into FDA panel for implantable CGM

March 5, 2018
By Stacy Lawrence

Polarity of circulating tumor cells plays role in the mechanism for cancer metastases

March 1, 2018
By Stacy Lawrence
Researchers have found that circulating tumor cells (CTCs) that go on to create metastases to spread cancer throughout the body may have particular polarity. This cellular polarity results in a specific shape that includes a 'nose' that invades tissue and then works to thrust the CTC into it and out of the blood stream.
Read More

Researchers create open-source AI to diagnose retinal health, other diseases

Feb. 28, 2018
By Stacy Lawrence

Memorial Sloan Kettering-backed Cota raises $40M for real-world data and analytics

Feb. 27, 2018
By Stacy Lawrence

FDA clears Endomag marker for long-term and soft tissue use, adding to breast cancer

Feb. 23, 2018
By Stacy Lawrence
View All Articles by Stacy Lawrence

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing